| Literature DB >> 23695446 |
Charlotte Teunissen1, Til Menge, Ayse Altintas, José C Álvarez-Cermeño, Antonio Bertolotto, Frode S Berven, Lou Brundin, Manuel Comabella, Matilde Degn, Florian Deisenhammer, Franz Fazekas, Diego Franciotta, Jette L Frederiksen, Daniela Galimberti, Sharmilee Gnanapavan, Harald Hegen, Bernhard Hemmer, Rogier Hintzen, Steve Hughes, Ellen Iacobaeus, Ann C Kroksveen, Jens Kuhle, John Richert, Hayrettin Tumani, Luisa M Villar, Jelena Drulovic, Irena Dujmovic, Michael Khalil, Ales Bartos.
Abstract
The choice of appropriate control group(s) is critical in cerebrospinal fluid (CSF) biomarker research in multiple sclerosis (MS). There is a lack of definitions and nomenclature of different control groups and a rationalized application of different control groups. We here propose consensus definitions and nomenclature for the following groups: healthy controls (HCs), spinal anesthesia subjects (SASs), inflammatory neurological disease controls (INDCs), peripheral inflammatory neurological disease controls (PINDCs), non-inflammatory neurological controls (NINDCs), symptomatic controls (SCs). Furthermore, we discuss the application of these control groups in specific study designs, such as for diagnostic biomarker studies, prognostic biomarker studies and therapeutic response studies. Application of these uniform definitions will lead to better comparability of biomarker studies and optimal use of available resources. This will lead to improved quality of CSF biomarker research in MS and related disorders.Entities:
Keywords: Biomarkers; cerebrospinal fluid; control groups; study design
Mesh:
Substances:
Year: 2013 PMID: 23695446 DOI: 10.1177/1352458513488232
Source DB: PubMed Journal: Mult Scler ISSN: 1352-4585 Impact factor: 6.312